Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Fengcai
  NCT04566770		 RCTCanSino (Convidecia)placeboCOVID-19 prophylaxis (excluding children)NA
320/110 safety concern
  • statistically significant 19.2-fold increase in systemic adverse reaction, any, dose 1
  • statistically significant 3.4-fold increase in systemic adverse reaction, any, dose 2
CanSino phase 2 (Zhu)
  NCT04341389		 RCTCanSino (Convidecia)placeboCOVID-19 prophylaxis (excluding children)NA
382/126 inconclusive
    No serious adverse events were documented within 28 days

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons